Patient Name : Mrs.

RUPA DAS Collected : 02/Apr/2025 02:04PM

Age/Gender : 57 Y 7 M 27 D /F Received : 02/Apr/2025 02:15PM
UHID/MR No : DJBH.0000044757 Reported : 02/Apr/2025 02:36PM
Visit ID : DLAYOPV4032 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC HRBR LAYOUT
IP/OP NO : Center location : Thazhampur,Chennai

DEPARTMENT OF BIOCHEMISTRY
GLUCOSE FASTING & PP

Test Name Result Unit Bio. Ref. Interval Method

GLUCOSE, FASTING , NAF PLASMA 112 mg/dL 70-100 HEXOKINASE

Comment:
As per American Diabetes Guidelines, 2023
Fasting Glucose Values in mg/dL Interpretation
70-100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
<70 mg/dL Hypoglycemia
Note:
1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of
> or = 200 mg/dL on at least 2 occasions.
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name Result Unit Bio. Ref. Interval Method

GLUCOSE, POST PRANDIAL (PP), 2 199 mg/dL 70-140 HEXOKINASE
HOURS , SODIUM FLUORIDE PLASMA (2
HR)

Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 1 of 4

SIN No:BI25051632
Patient Name : Mrs.RUPA DAS Collected : 02/Apr/2025 12:34PM
Age/Gender : 57 Y 7 M 27 D /F Received : 02/Apr/2025 02:09PM
UHID/MR No : DJBH.0000044757 Reported : 02/Apr/2025 03:24PM
Visit ID : DLAYOPV4032 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC HRBR LAYOUT
IP/OP NO : Center location : Thazhampur,Chennai

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA
HBA1C, GLYCATED HEMOGLOBIN 7.3 % HPLC
ESTIMATED AVERAGE GLUCOSE 163 mg/dL Calculated
(eAG)
Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is
advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may
not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 2 of 4

SIN No:BI25051633
Patient Name : Mrs.RUPA DAS Collected : 02/Apr/2025 12:34PM
Age/Gender : 57 Y 7 M 27 D /F Received : 02/Apr/2025 02:14PM
UHID/MR No : DJBH.0000044757 Reported : 02/Apr/2025 02:36PM
Visit ID : DLAYOPV4032 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC HRBR LAYOUT
IP/OP NO : Center location : Thazhampur,Chennai

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST (LFT) , SERUM
BILIRUBIN, TOTAL 0.51 mg/dL 0-1.2 Colorimetric
BILIRUBIN CONJUGATED (DIRECT) 0.13 mg/dL <0.2 DPD
BILIRUBIN (INDIRECT) 0.38 mg/dL 0.0-1.1 Calculated
ALANINE AMINOTRANSFERASE 24 U/L <35 IFCC
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 27.0 U/L <35 IFCC
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 1.1 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 122.00 U/L 30-120 IFCC
PROTEIN, TOTAL 6.63 g/dL 6.6-8.3 Biuret
ALBUMIN 4.00 g/dL 3.5-5.2 BROMO CRESOL
GREEN
GLOBULIN 2.63 g/dL 2.0-3.5 Calculated
A/G RATIO 1.52 0.9-2.0 Calculated

Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of
bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:
1. Hepatocellular Injury: *AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and
skeletal injuries.*ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for
hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with
ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This
ratio is also seen to be increased in NAFLD, Wilsons’s diseases, Cirrhosis, but the increase is usually not >2.Note- If both SGPT
and SGOT are within reference range then AST:ALT (De Ritis ratio) does not have any clinical significance.
2. Cholestatic Pattern:*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in
pregnancy, impacted by age and sex.*Bilirubin (Direct) and GGT elevated- helps to establish hepatic origin.
3. Synthetic function impairment:*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.

Page 3 of 4

SIN No:BI25051634
Patient Name : Mrs.RUPA DAS Collected : 02/Apr/2025 12:34PM
Age/Gender : 57 Y 7 M 27 D /F Received : 02/Apr/2025 03:48PM
UHID/MR No : DJBH.0000044757 Reported : 02/Apr/2025 03:49PM
Visit ID : DLAYOPV4032 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC HRBR LAYOUT
IP/OP NO : Center location : Thazhampur,Chennai

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Unit Bio. Ref. Interval Method

COMPLETE URINE EXAMINATION (CUE) , URINE
PHYSICAL EXAMINATION
COLOUR PALE YELLOW PALE YELLOW Visual
TRANSPARENCY HAZY CLEAR Physical Measurement
pH 5.5 5-7.5 Double Indicator
SP. GRAVITY 1.005 1.002-1.030 Bromothymol Blue
BIOCHEMICAL EXAMINATION
URINE PROTEIN NEGATIVE NEGATIVE Protein Error Of
Indicator
GLUCOSE POSITIVE +++ NEGATIVE Glucose Oxidase
URINE BILIRUBIN NEGATIVE NEGATIVE Azo Coupling Reaction
URINE KETONES (RANDOM) NEGATIVE NEGATIVE Sodium Nitro Prusside
UROBILINOGEN Normal NORMAL Modifed Ehrlich
Reaction
NITRITE NEGATIVE NEGATIVE Diazotization
LEUCOCYTE ESTERASE POSITIVE + NEGATIVE Leucocyte Esterase
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY
PUS CELLS 6-8 /hpf 0-5 Microscopy
EPITHELIAL CELLS 5-6 /hpf <10 Microscopy
RBC NIL /hpf 0-2 Microscopy
CASTS NIL 0-2 Hyaline Cast Microscopy
CRYSTALS ABSENT ABSENT Microscopy

Comment:
All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked
and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

*** End Of Report ***

Page 4 of 4

SIN No:C03600723
 Patient Name : Mrs.RUPA DAS Collected : 02/Apr/2025 12:34PM
Age/Gender : 57 Y 7 M 27 D /F Received : 02/Apr/2025 03:48PM
UHID/MR No : DJBH.0000044757 Reported : 02/Apr/2025 03:49PM
Visit ID : DLAYOPV4032 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC HRBR LAYOUT
IP/OP NO : Center location : Thazhampur,Chennai

TERMS AND CONDITIONS GOVERNING THIS REPORT

1. Reported results are for information and interpretation of the referring doctor or such other medical professionals,
who understandreporting units, reference ranges and limitation of technologies.Laboratories not be responsible for any
interpretation whatsoever.
2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the
verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies.
5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

SIN No:C03600723